175 related articles for article (PubMed ID: 25166132)
1. Is herpes zoster vaccination likely to be cost-effective in Canada?
Peden AD; Strobel SB; Forget EL
Can J Public Health; 2014 May; 105(4):e287-95. PubMed ID: 25166132
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
[TBL] [Abstract][Full Text] [Related]
5. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
10. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
11. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.
Le P; Rothberg MB
J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.
Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P
Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
[TBL] [Abstract][Full Text] [Related]
15. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]